濮阳东方妇科价格偏低(濮阳东方妇科医院做人流价格) (今日更新中)

BEIJING, July 25 (Xinhuanet) -- More than one in three births in the U.S. are  delivered by C-section, which is an all time high and an increase of 25 percent over seven years, according to news reports Monday quoting a new study.Based on data from 19 states, C-section, or Cesarean, deliveries shot up from 27 percent of all births in 2002 to 34 percent in 2009, said the study by HealthGrades.  HealthGrades is an independent health care ratings organization with information on physicians, dentists and 5,000 hospitals in the nation.The study noted that the states with the highest rates are Texas, New Jersey and Florida while Utah, Colorado and Wisconsin are the lowest.Experts hold C-section deliveries are most suitable when vaginal delivery puts the health of the woman or child at risk, but also attributing the reason of increase to convenience, less risk, fertility and general attitudes.However, Divya Cantor, MD, MBA and HealthGrades Senior Physician Consultant. cautioned, "C-sections are rising, and there needs to be a little bit more scrutiny from the person who is having the C-section as well as doctors and hospitals."

BEIJING, Sept. 11 (Xinhua) -- Despite a series of disasters, Chinese people tend to believe that the moon is still round and bright in the Mid-autumn Festival.Falling on Monday, the 15th day of the eighth month in the Chinese calendar, it is an important Chinese holiday, next only to the Spring Festival, and a chance for family reunion under the full moon, a symbol for happiness and prosperity.A staff worker shows newly-cooked moon cakes during a Mid-autumn festival celebration activity held in Tianjin, north China, Sept. 11, 2011. Some 100 children from Tianjin and southeast China's Taiwan attended the activity on Sunday.FAMILY REUNIONIn the railway station of Nanjing, capital city of east China's Jiangsu Province, passengers lined in long queues while waiting for their trains on Saturday.Although the three-day holiday seemed too short for a long trip, Xiao Liang carried several bags with him. "I bought wine for my dad, boiled salted duck for my mom, and health products for my grand parents," the young man beamed.In the southwestern Guangxi Zhuang Autonomous Region, Li Yukun didn't believe that she could reunite with her son for holiday. In fact, she never thought she could see the three-year-old boy again.Two years ago, Xiao Wei (pseudonym) from the Dalun village of the Beiliu city was kidnapped. His parents were desperate. "On special occasions like the Mid-autumn Festival, we shed tears while missing him," Li said.Police finally managed to get clues that a similar boy was adopted in the neighboring Guangdong Province.Li prepared for a feast with policemen to celebrate reunion with Xiao Wei.Since a campaign was launched to rescue trafficked children in Guangxi in 2009, 339 children were saved, half of whom had been sent back and could reunite with their parents in this festival.In Sichuan, 10 prisoners with good records in jail were given an opportunity to go back home for the holiday."In the past I could only receive greetings from my relatives behind the bars," a woman surnamed Chen said. "This year, my dream for home finally came true."Meanwhile, 171 prisoners had their jail terms shortened so that they could be released before the Mid-autumn Festival.

SAN FRANCISCO, July 6 (Xinhua) -- Facebook on Wednesday introduced a new video calling feature powered by Skype and some improvements to the chat designs on the social networking site.According to Facebook, users can reach video calling from a new "Call" button on a friend's profile or from the chat panel after downloading a Skype application. A recipient will receive an alert that they are being called and can then accept or decline.At the press event held at Facebook headquarters in Palo Alto, California, CEO Mark Zuckerberg said the feature will begin with one-on-one video chat. Skype CEO Tony Bates, whose company has been acquired by Microsoft, said Skype is considering having its paid product within the Facebook product.The social networking company also introduced "Ad Hoc Group Chat", which enables users to start a group chat instantly without creating a group with those multiple friends at first. The new group chat feature is also available for Facebook's mobile interfaces.Facebook also introduces a sidebar that lists the people a user messages most, enabling users to chat with close friends, professional contacts or co-workers without being interrupted. The sidebar can adjust with the size of users' browser window and automatically appears when the window is wide enough.In the opening remarks at the press event, Zuckerberg confirmed that Facebook had surpassed 750 million monthly active users. He said the company had declined to announce the number earlier because it has become focused on other metrics, like how actively users are sharing information.The CEO said users are now sharing 4 billion "things" on Facebook every day, which grew at an exponential rate compared to the amount users share a year ago."Social networking is at an inflection point," said Zuckerberg, adding that he believes social networking now is more about the strength of connecting people rather than the quantity of users or ubiquity of the technology.Zuckerberg presented a graph to show how Facebook product launches have helped drive the growth of sharing. He said the social network expects more innovations from other companies involved in everything from music to communication to help drive the growth.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

来源：资阳报